

Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics

Cellanyx Diagnostics News – Announcement of New Board Member Dr. Colin Brenan

February 1, 2013

Cellanyx is pleased to announce the appointment of Dr. Colin Brenan to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Dr. Brenan comes with tremendous business and leadership talent. Currently, Dr. Brenan is involved with HiFiBiO SAS as Chief Technology Officer and Senior Vice President, Business Development. Formerly he was Managing Director of the Monsanto-Atlas Seed Fund Alliance at Atlas Venture (Cambridge, USA) where he identified and invested in seed and early-stage life science companies. Prior to Atlas, Dr. Brenan was Director of Strategic Relationships for Center for Integration of Medicine and Innovative Technology (Boston, MA) where he implemented CIMIT's innovation strategy with external partners, raised \$6M in funding and launched a start-up (Organ Solutions) from the CIMIT Accelerator. Previous to joining CIMIT, Dr. Brenan was the Founder, Chief Technology Officer and Senior Vice President, Business Development for BioTrove Inc. (Woburn, USA), a life science tools and consumables company spun-out from the Massachusetts Institute of Technology (MIT) and acquired by Life Technologies Inc. (LIFE:NASDAQ); and a Founder of Biocius Inc., a drug development instrument and service provider spun-out from BioTrove and acquired by Agilent Inc. (A:NYSE). Dr. Brenan holds multiple patents and has published extensively in the fields of microsystem technologies applied to biological analysis. He received his B.Sc. (Honors Physics), M. Eng. (Electrical), and Ph.D. (Biomedical Engineering) from McGill University (Montreal, Canada) and completed post-doctoral training at MIT.

Dr. Brenan is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that he will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

###

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.
One Marina Park Drive,
14th floor
Boston, MA, 02210
Main: 571.212.9991
Email: info@cellanyx.com